ADMA Biologics (NASDAQ:ADMA) Shares Gap Up on Strong Earnings

Key Points

• ADMA shares surged after a strong quarterly report, opening at $12.01 versus the prior close of $10.48 and later trading at $13.044. Adjusted EPS of $0.23 and revenue of $141.1 million both topped analyst estimates.
• ASCENIV drove growth and profitability: revenue rose 31% to $124.7 million, while gross margin expanded to 71%; overall revenue increased 5% year over year.
• The company maintained its 2026 revenue outlook of at least $530 million and raised its minimum adjusted EBITDA forecast to $275 million, citing accelerating ASCENIV demand.

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report)'s stock price gapped up before the market opened on Thursday following a stronger than expected earnings report. The stock had previously closed at $10.48, but opened at $12.01. ADMA Biologics shares last traded at $13.0440, with a volume of 1,753,292 shares.

The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.03. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%. The business had revenue of $141.10 million during the quarter, compared to analysts' expectations of $138.11 million. During the same period in the prior year, the firm posted $0.15 EPS. ADMA Biologics's quarterly revenue was up 5.1% compared to the same quarter last year.

Key Stories Impacting ADMA Biologics

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Q3 revenue was $141.1 million, ahead of the $138.1 million consensus estimate, while adjusted EPS of $0.23 topped the $0.20 forecast. Revenue grew 5% year over year, and GAAP net income rose 37% to $49.9 million. ADMA Biologics Q3 results
• Positive Sentiment: ASCENIV revenue climbed 31% to $124.7 million, and gross margin expanded to 71% from a year earlier, supporting improved profitability and operating leverage. Q3 earnings and ASCENIV coverage
• Positive Sentiment: The company reiterated its 2026 revenue outlook of at least $530 million and raised its minimum adjusted EBITDA outlook to at least $275 million, citing accelerating ASCENIV demand. ADMA outlook update
• Neutral Sentiment: Cantor Fitzgerald raised its price target from $12 to $13 but kept a neutral rating, signaling a higher valuation objective without a more bullish analyst stance. Cantor Fitzgerald recommendations

Wall Street Analyst Weigh In

ADMA has been the subject of a number of analyst reports. Cantor Fitzgerald lifted their price objective on ADMA Biologics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Thursday. Zacks Research raised shares of ADMA Biologics from a "strong sell" rating to a "hold" rating in a report on Wednesday, September 2nd. Mizuho set a $18.00 target price on shares of ADMA Biologics in a report on Thursday. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of ADMA Biologics in a research report on Monday, September 14th. Three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $17.50.

Institutional Investors Weigh In On ADMA Biologics

Large investors have recently bought and sold shares of the business. NorthCrest Asset Manangement LLC increased its holdings in shares of ADMA Biologics by 8.4% in the third quarter. NorthCrest Asset Manangement LLC now owns 15,952 shares of the biotechnology company's stock valued at $165,000 after purchasing an additional 1,234 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in ADMA Biologics by 4.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 32,087 shares of the biotechnology company's stock worth $319,000 after purchasing an additional 1,316 shares during the last quarter. Pinnacle Wealth Planning Services Inc. lifted its holdings in ADMA Biologics by 33.1% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 5,721 shares of the biotechnology company's stock worth $57,000 after buying an additional 1,422 shares in the last quarter. CenterBook Partners LP lifted its holdings in ADMA Biologics by 1.8% during the 3rd quarter. CenterBook Partners LP now owns 81,607 shares of the biotechnology company's stock worth $819,000 after buying an additional 1,432 shares in the last quarter. Finally, Rockefeller Capital Management L.P. lifted its holdings in ADMA Biologics by 60.7% during the 4th quarter. Rockefeller Capital Management L.P. now owns 4,485 shares of the biotechnology company's stock worth $82,000 after buying an additional 1,694 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Price Performance

The stock has a market capitalization of $2.89 billion, a P/E ratio of 18.42 and a beta of 0.65. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.81 and a current ratio of 6.97. The stock has a 50-day simple moving average of $10.07 and a 200 day simple moving average of $10.93.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and commercializing plasma-derived biologic products for people with compromised or weakened immune systems. The company's activities include collecting human plasma, developing immune globulin therapies and manufacturing products for use in the prevention and treatment of certain infectious diseases.

ADMA's portfolio includes Asceniv, an intravenous immune globulin indicated for primary humoral immunodeficiency disease, and Bivigam, an intravenous immune globulin used for the treatment of primary humoral immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.